Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Market for Antidepressants in Japan Part II (1)
August 16, 2010
- SSP to Place Top Priority on Profit Ratio: President Shiono
August 16, 2010
- DSP: Former Sepracor Boosts Sales by 54.1%
August 16, 2010
- Wakamoto: Net Loss Increases to ¥132 Mil.
August 16, 2010
- Market for Antidepressants in Japan Part II (2)
August 16, 2010
- Daiichi Sankyo Aims to Enter Vaccine Market in Emerging Countries
August 16, 2010
- JPMA to Dispatch Investigation Tour Group to US, Europe
August 9, 2010
- Ono Accelerates Development in Oncology Field
August 9, 2010
- Promote Industry-Academia Alliances to Develop Advanced Bioimaging Technology: Dr Yonekura
August 9, 2010
- M3 Sues Mebix's Former Management Team for Inappropriate Accounting
August 9, 2010
- Market for Antidepressants in Japan Part I
August 9, 2010
- Information on Drug Safety Must Be Repeatedly Provided: Ms Furukawa of IMS Japan
August 9, 2010
- Kyowa Pharm., Taiyo Recall Their Theophylline Products
August 9, 2010
- Korosho Warns against Rhabdomyolysis due to ARBs
August 9, 2010
- Dr Teraoka Proposes Introduction of CU into Japan
August 9, 2010
- JGA to Expand Its Membership Base
August 9, 2010
- High Costs, Poor Communication Skills in English Cited as Japan's Major Challenges
August 9, 2010
- 23 Groups Call for Public Funding for Cervical Cancer Vaccination
August 9, 2010
- Anti-Flu Drug from Daiichi Sankyo Recommended for Approval
August 9, 2010
- Astellas Extends VelocImmune Technology License Agreement with Regeneron
August 9, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…